Which Is Better: COX2 or NSAID Plus PPI?

Kuritzky, Louis
November 2010
Travel Medicine Advisor;Nov2010, Vol. 20 Issue 11, p63
The article presents a reprint of the article "Which is Better: COX2 or NSAID Plus PPI?" by Louis Kuritzky, which appeared in the September 15, 2010 issue of "Internal Medicine Alert". One of the considered benefits of the development of cyclo-oxygenase (COX) selective nonsteroidal anti-inflammatory agents (NSAIDs) was the lack of effect on COX1 that would eliminate much of the gastrointestinal (GI) toxicity seen. It notes that over 16,500 deaths were attributable to NSAID-induced GI bleeding.


Related Articles

  • Antiinflamatory Agents Less Dangerous for Gastrointestinal Tract. Rodr�guez-T&eagrave;llez, Manuel; Arg�elles, F.; Herrer�as, J.M.; Ledro, D.; Esteban, J. // Current Pharmaceutical Design;Jul2001, Vol. 7 Issue 10, p951 

    NSAIDs represent one of the most commonly used therapeutic drug groups worldwide. 1.5percent of the world population is estimated as taking NSAIDs. However, their use is not risk free and gastrointestinal (GI) lesions do appear, which is indeed the main reason for their toxicity. Frequently...

  • NSAID-induced gastrointestinal damage: the biochemical consequences of the 'ion trapping' hypothesis. Sigthorsson, Gudmundur; Tibble, Jeremy; Mahmud, Taher; Bjarnason, Ingvar // Inflammopharmacology;2000, Vol. 8 Issue 1, p31 

    There is irrefutable evidence that cyclooxygenase-1 (COX-1) inhibition by itself is not the only factor in the development of the gastrointestinal damage of NSAIDs. One suggestion is that the 'topical' effect of NSAIDs is an important initiating factor in their toxicity ('ion trapping...

  • Cyclooxygenase-2 Inhibition and Side-effects of Non-steroidal Anti-inflammatory Drugs in the Gastrointestinal Tract. Meyer-Kirchrath, J.; Schror, K. // Current Medicinal Chemistry;Nov2000, Vol. 7 Issue 11, p1121 

    Inhibition of prostaglandin biosynthesis via inhibition of the fatty acid cyclooxygenase (COX) is the mechanism of action of non-steroidal anti-inflammatory drugs (NSAIDs). This results in an inhibition of the inflammatory and pain-producing activities of prostaglandins at a site of tissue...

  • NSAIDs: the Emperor's new dogma? Bjarnason I; Takeuchi K; Simpson R // Gut;Sep2003, Vol. 52 Issue 9, p1376 

    The spectacular marketing success of the selective cyclooxygenase 2 (COX-2) inhibitors is largely based on efficacy comparable with conventional non-steroidal anti-inflammatory drugs (NSAIDs) with vastly improved gastrointestinal safety. The additional key to the marketing success is the purity...

  • New dogmas or old? Whittle B J R // Gut;Sep2003, Vol. 52 Issue 9, p1379 

    Recent experimental studies may undermine our understanding of the gastrointestinal side effects of non-steroidal anti-inflammatory drugs and cast a shadow on the original concept that underpins the development of the recent addition to the clinical anti-inflammatory armamentarium, the COX-2...

  • Upper Gastrointestinal Toxicity of Alendronate. Lowe, Catherine E.; Depew, William T.; Vanner, Stephen J.; Paterson, William G.; Meddings, Jon B. // American Journal of Gastroenterology;Mar2000, Vol. 95 Issue 3, p634 

    OBJECTIVE: Alendronate is rapidly gaining widespread use in the treatment of osteoporosis. However, recent postmarketing surveys and endoscopic studies suggest that its use may be associated with significant predictable esophageal and gastric mucosal toxicity, similar to that of aspirin and...

  • What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). Wooltorton, Eric // CMAJ: Canadian Medical Association Journal;6/25/2002, Vol. 166 Issue 13, p1692 

    Discusses the use of non-steroidal anti-inflammatory agents (NSAID), which have been associated with gastrointestinal events. Safety concerns about selective cyclooxygenase-2 (COX-2) inhibitors such as rofecoxib (Vioxx) and celecoxib (Celebrex), which were developed as an alternative to NSAID;...

  • Fewer upper GI events seen with COX-2 inhibitor.  // Geriatrics;Feb2000, Vol. 55 Issue 2, p98 

    Highlights the association of the cyclooxegenase-2 inhibitor rofecoxib with a lower risk of serious upper gastrointestinal (GI) side effects than commonly prescribed anti-inflammatory drugs (NSAID) according to a study by researchers in California and England. Number of NSAID-related deaths in...

  • Study evaluates aspirin comedication rates among long-term COX-2 inhibitor users.  // Formulary;Sep2004, Vol. 39 Issue 9, p434 

    Evaluates aspirin comedication rates among long-term COX-2 inhibitor users. Lack of difference in gastrointestinal infection ulcer complication rates between celecoxib and nonselective NSAID; Percentage of comedication with over-the-counter pain relievers.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics